Earnings Report /
Egypt

Rameda Pharmaceuticals: Private sales drive revenue growth, solid bottom line growth

  • Private sales and covid related antivirals drive topline growth, but pressures margins

  • Solid revenues, lower finance and depreciation expenses drive bottom line growth

  • Well positioned to capture growth opportunities

Mariam Wael
Al Ahly Pharos Securities Brokerage
16 November 2021